Assembly Biosciences (ASMB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.20
- Estimate
- -$0.52
- Surprise
- +61.9%
- Revenue (period 2026-06-30)
- $13.4M
- Score today
- 6.3/10
Revenue source: xbrl.
How the report landed
Assembly Biosciences (ASMB) reported a narrower loss than forecast — adjusted EPS of -$0.20 against the -$0.52 estimate (a 61.9% beat on a still-unprofitable quarter).
Coverage in the report window
- Assembly Biosciences Q2 EPS $(0.20) Beats $(0.65) Estimate, Sales $13.374M Beat $8.599M Estimate — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates ASMB Sell at 6.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +61.9% surprise compares with a +117.0% four-quarter average.
What argues against it
- Quality below floor (1.7 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin 1.7%), High leverage (D/E 27.9)
- Momentum score 4.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $19.87
- Price target
- $44.54
- Stop
- $18.67
- Upside to target
- +124.2%
- Reward-to-risk
- 12.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
ASMB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $405.6M
- P/E (fwd)
- -7.7
- P/E (ttm)
- 19.2
- 52-week range
- $19.25–$39.71
- Off 52-week high
- 50.0%
- RSI (14)
- 44
- Volume vs avg
- 1.31×
- Score today
- 6.3/10